Another gene therapy has come under scrutiny in the Netherlands for its high price. ZIN, the Dutch health technology appraisal (HTA) body, says bluebird bio should reduce the price of Zynteglo (betibeglogene autotemcel), and agree to a pay-for-performance deal.
The Dutch minister for medical care and sport has placed Zynteglo, a one-time treatment for transfusion-dependent beta-thalassemia, in the so-called...








